Besim Ogretmen to Proteasome Inhibitors
This is a "connection" page, showing publications Besim Ogretmen has written about Proteasome Inhibitors.
Connection Strength
0.052
-
Phase I study of opaganib, an oral sphingosine kinase 2-specific inhibitor, in relapsed and/or refractory multiple myeloma. Ann Hematol. 2023 Feb; 102(2):369-383.
Score: 0.052
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.